Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Gains from Investment Securities (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Gains from Investment Securities for 3 consecutive years, with -$2000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities rose 85.71% to -$2000.0 in Q3 2025 year-over-year; TTM through Jun 2025 was -$12000.0, a 100.73% decrease, with the full-year FY2024 number at -$12000.0, down 100.73% from a year prior.
  • Gains from Investment Securities was -$2000.0 for Q3 2025 at Inhibrx Biosciences, down from $30000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $1.6 million in Q4 2023 to a low of -$1.4 million in Q2 2024.
  • A 3-year average of $203000.0 and a median of $0.0 in 2023 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: plummeted 800.0% in 2024, then surged 102.11% in 2025.
  • Inhibrx Biosciences' Gains from Investment Securities stood at $1.6 million in 2023, then tumbled by 100.86% to -$14000.0 in 2024, then skyrocketed by 85.71% to -$2000.0 in 2025.
  • Per Business Quant, the three most recent readings for INBX's Gains from Investment Securities are -$2000.0 (Q3 2025), $30000.0 (Q2 2025), and -$28000.0 (Q1 2025).